Last reviewed: June 7, 2026
Last updated: June 7, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide's journey from diabetes medication to weight loss therapy spans over a decade of clinical research and real-world application. The medication was first approved by the FDA for type 2 diabetes in 2017, but its weight loss effects became the focus of major clinical trials beginning in 2019. Today, PlexusDx delivers compounded semaglutide injection starting at $149 per month for patients across all 50 states.
When Did Semaglutide Begin Treatment for Weight Loss?
Semaglutide entered clinical development for weight management in 2014 when researchers started examining its effects on body weight in people with diabetes. The medication showed unexpectedly strong weight loss results during earlier diabetes trials, prompting pharmaceutical companies to pursue dedicated obesity studies. By 2019, the landmark STEP clinical trials began enrolling participants specifically to test semaglutide's safety and effectiveness for chronic weight management in non-diabetic adults.
The first weight loss indication for semaglutide came in June 2021 when regulatory approval was granted for once-weekly injection therapy in patients with obesity or overweight with weight-related conditions. This approval marked a turning point in obesity medicine, as semaglutide became one of the first GLP-1 receptor agonists developed specifically for weight loss rather than adapted from diabetes treatment. Clinical data showed participants taking semaglutide lost an average of 15% of body weight over 68 weeks compared to 2-3% with placebo.
Semaglutide Clinical Trials: What the Evidence Shows
The STEP program consisted of four major trials conducted between 2019 and 2021 involving over 4,500 participants with obesity and overweight conditions. Participants received weekly semaglutide injections at doses ranging from 0.5 to 2.4 milligrams while following a reduced-calorie diet and exercise program. Results demonstrated consistent weight loss across all four studies, with nearly 70% of participants achieving at least 5% body weight reduction and approximately 35% reaching 15% or greater weight loss.
Safety and tolerability data from these trials showed that the most common side effects were gastrointestinal symptoms including nausea, constipation, and vomiting—typically mild to moderate in severity and occurring during dose escalation phases. Cardiovascular benefits also emerged from the research, with participants showing improvements in blood pressure, cholesterol levels, and reduced risk of major cardiovascular events. Long-term follow-up studies extending beyond the initial trial periods confirmed that weight loss benefits persisted with continued treatment over 2-3 years.
From Diabetes Treatment to Obesity Medicine: Semaglutide's Evolution
Semaglutide was originally developed as a once-weekly injectable GLP-1 receptor agonist for type 2 diabetes management, receiving FDA approval in December 2017 under the brand name Ozempic. Physicians and patients quickly noticed that people with diabetes taking semaglutide experienced significant weight reduction as a secondary benefit. This clinical observation prompted researchers to investigate whether semaglutide could be an effective standalone treatment for people without diabetes but struggling with excess weight.
The shift in clinical focus represented a broader recognition within medicine that obesity requires dedicated, evidence-based pharmacological treatment approaches. Prior to semaglutide's approval for weight loss, few prescription medications offered meaningful, sustained weight reduction. The success of semaglutide trials demonstrated that medications targeting GLP-1 pathways could deliver weight loss results comparable to or exceeding earlier obesity treatments, fundamentally changing how clinicians approach chronic weight management.
How PlexusDx Brings Semaglutide Therapy to More Patients
PlexusDx compounded semaglutide injection provides access to this proven weight loss therapy without requiring insurance coverage or membership fees. All medications come from licensed 503A compounding pharmacies ensuring quality and safety standards identical to brand-name formulations. PlexusDx serves all 50 states with flat monthly pricing starting at $149, meaning patients' costs remain stable regardless of dose adjustments as their treatment progresses.
Many patients benefit from PlexusDx's optional Precision Peptide Genetic Test ($99 add-on after the first treatment month), which analyzes 14 metabolic pathways and 49 peptides to identify individual genetic predispositions affecting weight loss response. Genetic variants in the GLP1R, GIPR, FTO, and MC4R genes influence how effectively semaglutide works for each person. Understanding these genetic factors allows PlexusDx providers to personalize dosing and potentially combine semaglutide with complementary peptide therapies for optimized outcomes. Patients can also use HSA or FSA accounts to cover treatment costs.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How long has semaglutide actually been available for weight loss treatment?
Semaglutide received FDA approval specifically for weight management in June 2021, making it available for obesity treatment for approximately three years through brand products and compounded versions. However, the medication was used off-label for weight loss starting around 2019-2020 when diabetes patients demonstrated remarkable results. PlexusDx has been providing compounded semaglutide injection to patients nationwide, ensuring access without insurance requirements.
What percentage of people lose weight with semaglutide based on clinical trials?
In the STEP clinical trials, approximately 70% of participants achieved at least 5% body weight loss, while 35% reached 15% or greater weight reduction over 68 weeks. These results significantly outperformed placebo groups where only 2-3% of participants lost meaningful weight. Individual outcomes vary based on adherence, diet, exercise, and genetic factors that PlexusDx can assess through Precision Peptide Genetic Testing.
Can I afford semaglutide through PlexusDx without insurance?
Yes, PlexusDx compounded semaglutide injection starts at $149 per month with no insurance required and no membership fees. Treatment is HSA/FSA eligible, which can reduce your actual out-of-pocket costs. Pricing remains flat regardless of dose changes, ensuring predictable monthly expenses as your treatment progresses.
What are the most common side effects of semaglutide for weight loss?
The most frequently reported side effects are gastrointestinal symptoms including nausea, vomiting, constipation, and diarrhea, typically occurring during dose escalation and generally mild to moderate in severity. Most side effects diminish after the first few weeks as your body adjusts. Serious adverse events are rare, and clinical trial data shows cardiovascular benefits including blood pressure and cholesterol improvements in many patients.
Does PlexusDx genetic testing help predict how well semaglutide will work for me?
PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence weight loss response and medication effectiveness. By identifying your individual genetic predispositions across 14 metabolic pathways and 49 peptides, providers can personalize your semaglutide dose and determine whether combining it with other peptide therapies may optimize your results. The test costs $99 as an add-on after your first treatment month.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Drink Alcohol on GLP-1s? What Our Experts Say for 2026
Can You Take Laxatives with Ozempic? What You Need to Know